Basking Biosciences

Basking Biosciences is a U.S.-based developer of therapies for acute ischemic stroke (AIS), focusing on creating a reversible thrombolytic treatment for AIS and leveraging biochemical properties to develop aptamers with high affinity and specificity for proteins involved in coagulation and hemostasis. The company’s lead development candidate, DTRI-031, is an RNA aptamer that inhibits von Willebrand Factor (vWF). Basking is also co-developing a matched oligonucleotide reversal agent, DTRI-025, to rapidly reverse the effects of DTRI-031 as needed.